We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Insists Humira Biosimilar Does Not Infringe AbbVie’s Patents
Amgen Insists Humira Biosimilar Does Not Infringe AbbVie’s Patents
Amgen is contesting AbbVie’s allegations that its Humira biosimilar, Amjevita, infringes dozens of patents, saying AbbVie failed to raise at least six of those patents in regulatory submissions.